FDA fast tracks Pfizer’s C. diff vaccine

The U.S. Food and Drug Administration has granted Fast Track designation to Pfizer’s investigational Clostridium difficile vaccine, which is in Phase 2 clinical development.

Advertisement

The FDA’s Fast Track is designed to facilitate the development and expedite the review of new vaccines intended to treat or prevent serious conditions and address unmet medical need, according to Pfizer.

Pfizer’s vaccine is designed to prevent diseases associated with C. diff, which can include life-threatening diarrhea and pseudomembranous colitis. Currently, there is no C. diff vaccine, even though C. diff- related diseases lead to about 14,000 deaths in the United States each year.

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Clinical Leadership & Infection Control

Advertisement

Comments are closed.